Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
22 participants
OBSERVATIONAL
2007-05-31
2010-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
4D Cone Beam CT Reconstruction for Radiotherapy Via Motion Vector Optimization
NCT03551405
A Phase I Evaluating Integration of HypofractionatedStudy Renal Ablative Radiotherapy
NCT02264548
Evaluation of Bladder Volumes in Patients Receiving Radiotherapy to the Rectum, Using Kilovoltage Cone-beam Imaging
NCT01033682
MVCT Imaging Pilot Study Using Helical Tomotherapy
NCT00168142
Multiple Respiration-Correlated Cone Beam Computed Tomography (CT) Scans to Reduce Target Positioning Errors in Radiotherapy Treatment of Thoracic Cancer
NCT00722605
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* receiving radical concurrent chemoradiotherapy
* no prior chest RT
* no prior surgical resection of lung tumor
* no prior chemotherapy
* patients' lung tumors should be centrally-located to minimize the effect of respiratory motion
* patient has biopsy proven TCC bladder
* receiving radical concurrent chemoradiotherapy or RT alone
* no prior chemotherapy
* patient signs study-specific consent form
Exclusion Criteria
* patient not being treated with concurrent chemoradiotherapy
* chemoradiotherapy given sequentially
* previous chest RT
* previous chemotherapy
* prior surgical resection of lung mass
* patient ineligible for pelvic RT
* patient does not sign study consent
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cross Cancer Institute
OTHER
AHS Cancer Control Alberta
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Don Yee, MD
Role: PRINCIPAL_INVESTIGATOR
AHS Cancer Control Alberta
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cross Cancer Institute
Edmonton, Alberta, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LU-11-0073
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.